globenewswire
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancerDALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. NASDAQ:CGON today announced the p…